This FDA approval for a pediatric indication transforms the commercial opportunity for Afrezza. Monitor next quarterly revenue and prescription trends for pediatric uptake. Historical performance shows MNKD can move violently (T+20 -29% on a bullish report previously), so position sizing should account for binary risk.
Price Chart
Executive Summary
MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the addressable patient population for the company's inhaled insulin product, a significant label expansion for a single-product biotech with a $1.1B market cap. The stock has a history of high volatility on news events.
Key Facts
- FDA approved Afrezza for use in children and adolescents aged 6+ with diabetes
- This is a label expansion for MannKind's sole marketed product, Afrezza
- Company has a $1.1B market cap — early-stage biotech dynamics apply
Financial Impact
Afrezza is MannKind's only commercial product; approval in pediatric population (ages 6+) expands TAM meaningfully. No revenue or market size figures provided in press release.
Risk Factors
- Pediatric adoption of inhaled insulin may be slow due to safety perception or switching costs
- Single-product concentration risk remains — Afrezza still competes with injectable insulins and GLP-1 agonists
- No financial guidance or revenue contribution projections provided in this release
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303773 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | Press Release | $3.85 $4.09 | ▲ +6.23% | ▲ +1.21% | $3.80 (−1.30%) |
Jul 24, 2026 10w ago | 8-K | $3.95 $4.07 | ▲ +3.04% | ▼ −0.26% | $3.80 (−3.80%) |
Jul 18, 2026 10w ago | Insider Cluster | $3.98 $3.90 | ▼ −2.01% | ▼ −6.13% | $3.80 (−4.52%) |
Jun 3, 2026 17w ago | Press Release | $3.36 $4.52 | ▲ +34.52% | ▲ +35.52% | $3.80 (+13.10%) |
Jun 2, 2026 17w ago | 8-K | $3.43 $4.05 | ▲ +18.08% | ▲ +19.64% | $3.80 (+10.79%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.80 (+0.80%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.80 (+0.80%) |
May 28, 2026 18w ago | 8-K | $3.64 $4.14 | ▲ +13.74% | ▲ +16.88% | $3.80 (+4.40%) |
May 27, 2026 18w ago | Press Release | $3.55 $3.93 | ▲ +10.70% | ▲ +12.61% | $3.80 (+7.04%) |
May 12, 2026 20w ago | Insider Cluster | $3.28 $3.63 | ▲ +10.67% | ▲ +12.40% | $3.80 (+15.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access